Rapid Review Quiz: COVID-19 Updates

Michael Stuart Bronze, MD

Disclosures

September 28, 2022

According to the CDC, no drugs are approved by the FDA for postexposure prophylaxis. Until recently, bebtelovimab was used for postexposure prophylaxis in patients at high risk for progression to severe COVID-19. Tixagevimab plus cilgavimab had been used for preexposure prophylaxis in individuals who were moderately to severely immunocompromised. Other monoclonal antibodies, including casirivimab/imdevimab and sotrovimab, were also previously used for postexposure prevention but are no longer used due to decreased efficacy against variants. 

Learn more about COVID-2019.

This Rapid Review Quiz was excerpted and adapted from the Medscape articles Paxlovid Reduces Risk of COVID Death by 79% in Older Adults: Study; Nirmatrelvir/Ritonavir (Paxlovid); Is It COVID or Long COVID? Your Organs May Know; Coronavirus Resource Center; Coronavirus Disease 2019 (COVID-19) in Children; Long COVID Doubles Risk of Some Serious Outcomes in Children, Teens; Regular Physical Activity May Fight Infection, Illness From COVID: Study; Coronavirus Disease 2019 (COVID-19); COVID Smell Loss Tops Disease Severity as a Predictor of Long-term Cognitive Impairment; Sore Throat, Cough Now Top COVID Symptoms: UK Study; and COVID Skin Signs Vary by Type of Variant, UK Study Finds.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....